Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s MoonLake Immunotherapeutics MLTX Stock Holding History

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-85	Closed	-$3.32K	–	58
2025 Q1	$3.32K	Hold	85	–	–	﹤0.01%	54
2024 Q4	$4.6K	Sell	85 -228,944	-100%	-$11.7M	﹤0.01%	52
2024 Q3	$11.5M	Buy	229,029 +226	+0.1%	+$10.6K	1.6%	26
2024 Q2	$10.1M	Sell	228,803 -427	-0.2%	-$18.1K	1.64%	23
2024 Q1	$11.5M	Buy	229,230 +238	+0.1%	+$12.9K	1.78%	22
2023 Q4	$13.8M	Buy	+228,992	New	+$11.8M	3.15%	15

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's MLTX Position: Q2 2025 in Review

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2025, closing a stake of 85 shares — an estimated $3.32K sold.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in MLTX in Q4 2023 and held it in 6 quarters. The position peaked at $13.8M in Q4 2023. 130 funds tracked by Wall St. Rank hold MLTX as of Q2 2025.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne reported no remaining MoonLake Immunotherapeutics position as of Q2 2025 after selling out during the quarter.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold 85 MoonLake Immunotherapeutics shares in Q2 2025, an estimated $3.32K.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in MoonLake Immunotherapeutics in Q4 2023 and held it in 6 quarters.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's MoonLake Immunotherapeutics position peaked at $13.8M in Q4 2023.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2025.

Based on Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's 13F filing for Q2 2025, filed 25 Jul 2025.